FDA authorizes marketing of first next-generation sequencing test for detecting HIV-1 drug resistance mutations |
News and Updates
eMediNexus Coverage from: 
FDA authorizes marketing of first next-generation sequencing test for detecting HIV-1 drug resistance mutations

0 Read Comments                

The U.S. Food and Drug Administration authorized marketing of a test to detect human immunodeficiency virus (HIV) Type-1 drug resistance mutations using next generation sequencing (NGS) technology. The Sentosa SQ HIV Genotyping Assay is the first HIV drug resistance assay that uses NGS technology that the FDA has authorized for marketing in the U.S… (FDA, November 5, 2019)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now